Objective: To understand the current antiviral treatment status and various clinical types of treatment plans in Xiamen City so as to explore ways to improve and optimize the diagnosis and treatment standards for chronic hepatitis B. Methods: A cross-sectional survey method was used to study the antiviral treatment status and treatment plans for chronic hepatitis B patients who visited and were diagnosed in the Department of Infectious Diseases and Hepatology of all tertiary hospitals in Xiamen City at 0:00~23:59 on May 25, 2022. Results: A total of 665 cases were surveyed in this study, with an antiviral treatment rate of 81.2%(540/665). The antiviral treatment rate of patients who accorded with the current guidelines for antiviral treatment indications was 85.8%(507/591). The antiviral treatment rate for 362 outpatients was 72.9%(264/362). Among them, the antiviral treatment rates were 80.1%, 89.3%, and 25.0%(226/282, 25/28, 13/52), respectively, for patients diagnosed with chronic hepatitis B, hepatitis B cirrhosis, and hepatitis B surface antigen-carrying status. The treatment plan for all outpatient patients was mainly oral nucleos(t)ide analogues, accounting for 59.1%(214/362). The antiviral treatment rate for 303 inpatients was 91.1%(276/303). The various clinical types of antiviral therapy rates among all patients were 70%~95%. The antiviral treatment plan for inpatients was mainly based on pegylated interferon alpha treatment, accounting for 72.6%(220/303). Conclusion: Antiviral treatment for chronic hepatitis B in Xiamen City can still be strengthened to meet the current demand for expanding antiviral treatment indications. Antiviral treatment rates and various types of treatment plans differ between outpatients and inpatients; thus, further awareness and acceptance of the goal of improving antiviral therapy, especially in outpatients, and the possibility for a clinical cure based on pegylated interferon alpha treatment are needed to maximize the benefit to more patients.
目的： 了解厦门市目前各个临床类型的慢性乙型肝炎患者的抗病毒治疗情况及治疗方案，探讨慢性乙型肝炎诊疗规范的提升和优化途径。 方法： 采用横断面研究方法分析2022年5月25日0∶00～23∶59时在厦门市全部三级医院感染科、肝病科就诊和住院且诊断明确的慢性乙型肝炎患者抗病毒治疗情况及治疗方案。 结果： 本研究共调查了665例患者，抗病毒治疗率为81.2%（540/665），符合目前指南抗病毒治疗指征的患者的抗病毒治疗率为85.8%（507/591）。362例门诊患者抗病毒治疗率为72.9%（264例），其中诊断为慢性乙型肝炎、乙型肝炎肝硬化、乙型肝炎表面抗原携带状态患者的抗病毒治疗率分别为80.1%、89.3%、25.0%（226/282、25/28、13/52例）。所有门诊患者治疗方案以口服核苷（酸）类似物为主，占59.1%（214例）。303例住院患者抗病毒治疗率为91.1%（276例），不同临床类型的患者抗病毒治疗率均在70%～95%之间。住院患者抗病毒治疗方案以基于聚乙二醇干扰素α治疗为主，达到72.6%（220例）。 结论： 厦门地区慢性乙型肝炎的抗病毒治疗仍可继续加强，以符合目前扩大抗病毒治疗适应证的需求。门诊患者和住院患者的抗病毒治疗率及治疗方案类型存在差异，需进一步提高患者尤其是门诊患者对抗病毒治疗目标以及基于聚乙二醇干扰素α治疗可达临床治愈的认识和接受度，从而使更多患者获益最大化。.
Keywords: Antiviral therapy; Chronic hepatitis B; Cross-sectional survey.